
Renewed certification maintains Kincardine’s role in Canopy Growth’s EU GMP flower supply chain


Canopy Growth Corporation (&#34;Canopy Growth&#34;, &#34;our&#34;, &#34;we&#34; or the &#34;Company&#34;) (TSX:WEED)

<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">Renewed certification maintains Kincardine’s role in Canopy Growth’s EU GMP flower supply chain</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/quote/WEED">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CGC">CGC</a>), a leading global company committed to bettering lives through cannabis, today announced that its Kincardine, Ontario cultivation facility ("Kincardine") has received renewed European Union Good Manufacturing Practice ("EU GMP") certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg.

</p><p xmlns="http://www.w3.org/1999/xhtml">
With its EU GMP status renewed, Canopy Growth can continue supplying Canadian-grown cannabis from Kincardine to medical cannabis markets across Europe.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"This renewal reflects the quality, consistency, and reliability of our cultivation operations at Kincardine and our commitment to supplying high-quality EU GMP flower directly from Canada," said Luc Mongeau, Chief Executive Officer, Canopy Growth. "As our business in Europe grows, we are continuing to broaden our flower portfolio, including through the introduction of MTL Cannabis genetics and additional strains, to meet the evolving needs of patients across the region."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Kincardine is the anchor asset of Canopy Growth’s complete end-to-end EU GMP flower supply chain, connecting Canadian cultivated flower to European distribution capabilities through Canopy Growth’s second EU GMP facility in Sankt Leon-Rot, Germany. Its renewed certification comes as the Company continues to see momentum in Europe, which helped drive a 10% year-over-year increase in international cannabis net revenue in the first quarter of fiscal 2027.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Canopy Growth</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company’s portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category-defining Storz &amp; Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada’s leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives.

</p><p xmlns="http://www.w3.org/1999/xhtml">
For more information visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.canopygrowth.com%2F&amp;esheet=54589299&amp;newsitemid=20260814529272&amp;lan=en-US&amp;anchor=www.canopygrowth.com&amp;index=1&amp;md5=6d52e1acd48e6acbe494cca231e4aeb8" shape="rect">www.canopygrowth.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260814529272r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260814529272/en/" rel="nofollow">https://www.businesswire.com/news/home/20260814529272/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact: </b><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:media@canopygrowth.com" shape="rect">media@canopygrowth.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br><b xmlns="http://www.w3.org/1999/xhtml">Investor Contact:</b> <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:invest@canopygrowth.com" shape="rect">invest@canopygrowth.com</a>

</p>

TSX:WEED

Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows

Kincardine EU GMP renewal strengthens Canopy Growth's European supply chain

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Renewed certification maintains Kincardine’s role in Canopy Growth’s EU GMP flower supply chain


Canopy Growth Corporation (&amp;#34;Canopy Growth&amp;#34;, &amp;#34;our&amp;#34;, &amp;#34;we&amp;#34; or the &amp;#34;Company&amp;#34;) (TSX:WEED)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Canopy Growth announced renewed EU GMP certification for its Kincardine, Ontario facility, enabling continued Canadian-grown cannabis exports to Europe and reinforcing its EU supply network alongside the Sankt Leon-Rot facility. The update follows momentum in Europe, with international cannabis net revenue rising 10% year over year in Q1 FY2027, suggesting upside from expanded strains and portfolio. This supports a longer-term growth thesis in Europe and Canada-U.S. cross-border operations.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kincardine EU GMP renewal secures continued EU medical-cannabis supply from Canada.</li><li>EU supply chain anchors Canopy Growth&#039;s European growth, aided by Sankt Leon-Rot facility.</li><li>International cannabis net revenue up 10% YoY in Q1 FY2027.</li><li>Kincardine anchors EU flower supply chain as a hub for Europe export.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Canopy Growth Corporation (WEED)</strong>: TSX:WEED and NASDAQ:CGC; EU GMP renewal strengthens Europe-focused supply chain and growth prospects.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News; regulatory certification reinforces Canopy Growth&#039;s execution and supply chain strategy in Europe.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Renewed EU GMP cert reduces regulatory risk for European sales.</li><li>Momentum in Europe drives international cannabis revenue growth (10% YoY).</li><li>Kincardine anchors Canopy&#039;s EU supply chain with Germany facility.</li><li>Potential for expanded strains and MTL Cannabis genetics in Europe.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Kincardine, Ontario facility renewed EU GMP certification.</li><li>Certification granted by Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg.</li><li>Q1 FY2027 international cannabis net revenue up 10% YoY.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on TSX:WEED over the next 1–3 months as EU certification supports Europe-driven revenue growth.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">Renewed certification maintains Kincardine’s role in Canopy Growth’s EU GMP flower supply chain</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/quote/WEED">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CGC">CGC</a>), a leading global company committed to bettering lives through cannabis, today announced that its Kincardine, Ontario cultivation facility ("Kincardine") has received renewed European Union Good Manufacturing Practice ("EU GMP") certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg.

</p><p xmlns="http://www.w3.org/1999/xhtml">
With its EU GMP status renewed, Canopy Growth can continue supplying Canadian-grown cannabis from Kincardine to medical cannabis markets across Europe.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"This renewal reflects the quality, consistency, and reliability of our cultivation operations at Kincardine and our commitment to supplying high-quality EU GMP flower directly from Canada," said Luc Mongeau, Chief Executive Officer, Canopy Growth. "As our business in Europe grows, we are continuing to broaden our flower portfolio, including through the introduction of MTL Cannabis genetics and additional strains, to meet the evolving needs of patients across the region."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Kincardine is the anchor asset of Canopy Growth’s complete end-to-end EU GMP flower supply chain, connecting Canadian cultivated flower to European distribution capabilities through Canopy Growth’s second EU GMP facility in Sankt Leon-Rot, Germany. Its renewed certification comes as the Company continues to see momentum in Europe, which helped drive a 10% year-over-year increase in international cannabis net revenue in the first quarter of fiscal 2027.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Canopy Growth</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company’s portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category-defining Storz &amp; Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada’s leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives.

</p><p xmlns="http://www.w3.org/1999/xhtml">
For more information visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.canopygrowth.com%2F&amp;esheet=54589299&amp;newsitemid=20260814529272&amp;lan=en-US&amp;anchor=www.canopygrowth.com&amp;index=1&amp;md5=6d52e1acd48e6acbe494cca231e4aeb8" shape="rect">www.canopygrowth.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260814529272r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260814529272/en/" rel="nofollow">https://www.businesswire.com/news/home/20260814529272/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact: </b><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:media@canopygrowth.com" shape="rect">media@canopygrowth.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br><b xmlns="http://www.w3.org/1999/xhtml">Investor Contact:</b> <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:invest@canopygrowth.com" shape="rect">invest@canopygrowth.com</a>

</p>

Canopy Growth announced renewed EU GMP certification for its Kincardine, Ontario facility, enabling continued Canadian-grown cannabis exports to Europe and reinforcing its EU supply network alongside the Sankt Leon-Rot facility. The update follows momentum in Europe, with international cannabis net revenue rising 10% year over year in Q1 FY2027, suggesting upside from expanded strains and portfolio. This supports a longer-term growth thesis in Europe and Canada-U.S. cross-border operations.

News insight

Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows

AI summary

Sentiment rationale

Key facts

Industry News